Although it is commonly argued that there is a mismatch between drug innovation and disease burden, there is little evidence on the magnitude and direction of such disparities. In this paper, we measure inequality in innovation, by comparing research and development activity with population health and gross domestic product data across 493 therapeutic indications to globally measure:
| INTRODUCTION
It is commonly argued that there is a misalignment between pharmaceutical innovation and global health needs (Kremer, 2002; Kremer & Glennerster, 2004; Lanjouw & Cockburn, 2001) as indicated by the latest figures on global pharmaceutical research and development (R&D) investments and the global burden of disease. Whether measured using the number of new chemical entities (NCEs) or the average sales per therapeutic area, R&D investment has mainly targeted five therapeutic areas since 1990 (Pammolli, Magazzini, & Riccaboni, 2011) , namely, (a) antineoplastics (53.2% of total R&D investment), (b) antibacterials and antimycotics (18.4%), (c) treatments targeting the central nervous system (15.5%), (d) therapies for metabolism conditions (8.8%), and (e) therapies to treat cardiovascular diseases (6.2%).
These proportions correspond closely to pharmacological areas associated with high disease prevalence in Western Europe, North America, and Australasia (namely, neoplasms, and mental and behavioral disorders; Murray et al., 2013) . However, the majority of the world's population lives in developing countries, for whom the disease burden is still mostly caused by infectious diseases and neonatal conditions (Murray et al., 2013) , in stark contrast to the observed pattern of pharmaceutical innovation (Trouiller et al., 2002) .
Although these figures hint at the apparent misalignment between global drug innovation and burden of disease (Table 1) , they cannot provide us with an accurate assessment of the nature and magnitude of that misalignment. Such assessment requires a reconciliation of previously unrelated data sources to compare the distributions of innovation and burden of disease. This is the starting point of this study.
Two main reasons are generally put forward for the apparent mismatch. First, there are disease areas in which it is relatively more difficult to innovate. Therapies targeting these diseases are scientifically challenging and pose substantial health safety issues. For instance, limited understanding of the basic science underlying diseases of the central nervous system has meant that identification of feasible drug targets for Alzheimer, Parkinson, and other degenerative neurological disorders is challenging (Martino, Ward, Packer, Simpson, & Stevens, 2012; Mohs & Greig, 2017) . Second, firms act strategically when determining their R&D investments concentrating their efforts on therapies targeted at more profitable markets, i.e., therapies associated with high disease prevalence and incidence and high willingnessto-pay. There is therefore a lack of R&D activity targeting disease markets that are less attractive because of lower potential revenue from a new medicine, either because of low disease prevalence or affordability (Drummond, Wilson, Kanavos, Ubel, & Rovira, 2007; Dukes, 2002; Pecoul, Chirac, Trouiller, & Pinel, 1999) . The absence of incentive mechanisms promoting R&D in riskier, or less profitable, disease areas may have contributed to a lack of innovation in therapeutic areas with potentially large economic and health impacts (Kremer & Glennerster, 2004; Pecoul et al., 1999; Scott Morton & Kyle, 2011) .
In order to inform policies to better align R&D activity with societal needs, it is essential to secure more evidence to identify the nature and magnitude of the mismatches between drug innovation and disease burden at a global level. The literature provides important first insights with regards to the correlation between therapeutic innovation and disease burden, but has certain shortcomings that we seek to mitigate in our analysis. These limitations relate to (a) the (Pammolli et al., 2011) Number of NCEs (1990 NCEs ( -2007 Top five therapeutic areas (Pammolli et al., 2011) Average sales ($US million; 1990 -2007 measurement of drug innovation, (b) the scope of the analysis, and (c) the methods used to assess health inequalities in drug innovation.
With regards to the measurement of innovation, some studies have focused on clinical trials rather than market launches (Viergever, Terry, & Karam, 2013) and, therefore, fail to capture the potential innovations that are in practice made available to the population. This is a concern as many projects in the R&D pipeline fail to reach the market (either for regulatory or commercial reasons) and, therefore, fail to target existing disease burden.
Other papers measure innovation as market launches but focus on non-representative samples of drug innovation and thus suffer from sample selection bias. Catalá-López, García-Altés, Álvarez-Martín, Gènova-Maleras, and MorantGinestar (2010) look at market registrations issued through the single centralized procedure by the European Medicines Agency (EMA), between 1995 and 2009, in order to examine whether drug innovation in the EMA region targets the most relevant conditions from a global public health perspective. Their analysis, thus, fails to capture other drug market authorizations, including those issued through country specific procedures, which may potentially affect inequalities in drug innovation.
The analysis by Lichtenberg (2005) is closer to ours in that the author uses the same data sources. However, the data used in his analysis is incomplete as the author can only match products launched in the market with disease burden data for a subset of drugs and countries. The study also lacks information of burden of disease at country level, instead using regional level data, split in between developing and developed countries.
Other studies proxy innovation in ways that suffer from publication or reporting bias by counting the number of published economic evaluations (Catalá-López et al., 2011; Neumann et al., 2005) , published clinical evidence (Kaplan et al., 2013; Kaplan & Laing, 2004) , or reported innovations (Martino et al., 2012) . Beyond publication bias, economic evaluations are a poor proxy for innovation as not all marketed drugs go through these appraisals in all countries.
The paper by Martino et al. (2012) proxies innovation with the number of technologies uploaded onto EuroScan by EuroScan member agencies. The data are self-reported, and member agencies include only 17 countries and, therefore, are not representative of their target population of innovation. Finally, the contributions by Kaplan et al. (2013) and Kaplan and Laing (2004) proxy innovation with the efficacy of drugs reported in the Cochrane Database of Systematic Reviews. Their data only captures drugs that have been reported in the literature, most likely in clinical trials studies, and, therefore, suffer from publication bias. Published evidence does not distinguish between innovations available in the market from those still on the R&D pipeline that may potentially never reach the population to address unmet need and includes drugs that may no longer be used in clinical practice.
The second limitation relates to the scope of the studies that restrict their analysis to therapeutic indications or disease areas (Lichtenberg, 2005; Martino et al., 2012) and/or groups of countries (Catalá-López et al., 2010; Catalá-López et al., 2011; Kaplan et al., 2013; Kaplan & Laing, 2004; Neumann et al., 2005) . By focusing on the United States and Europe, these studies fail to capture disease burden associated with diseases affecting low and middle-income countries and, therefore, present a narrow picture of global inequalities.
Third, methodologically, the existing literature either uses a simple disease ranking exercise of mortality and disease burden, making no statistical association with the disease-specific measure of drug innovation (Kaplan et al., 2013; Kaplan & Laing, 2004) or performs correlation analysis which assumes monotonicity (Catalá-López et al., 2010; Catalá-López et al., 2011; Martino et al., 2012; Neumann et al., 2005) . Moreover, none of the studies measures inequalities between and within diseases groups over time, in terms of health needs and in regards to the ability-to-pay of countries.
Therefore, we add to this literature in four significant ways: (a) we measure innovation by counting the global market launches in all countries, across all therapeutic indications and disease areas that can be targeted by NCEs, between 1990 and 2010, ensuring a comprehensive scope of analysis and not imposing sample bias; (b) methodologically, we also improve on the literature by using concentration curves and concentration indices in order to measure the magnitude and statistical significance of the mismatch between drug innovation and disease burden; (c) we measure inequalities across and within disease groups; and (d) we measure inequality both in terms of disease burden and ability-to-pay between 1990 and 2010.
| METHODS
We perform four types of analysis. In the first, we measure the correspondence between drug innovation and global disease burden and global market size across all diseases. In the second, we carry out separate analysis for the two broadest disease groups as defined by the GBD study (Murray et al., 2013) , that is communicable diseases (CDs) and non-communicable diseases (NCDs). In the third, we refine the analysis by examining disease groups 1 belonging to the broad groups of CDs and NCDs causing the highest disability in developed and developing countries (using the country classification used by the GBD study; Murray et al., 2013) . Finally, given its global public health relevance (Murray et al., 2013) , we also present the case of malaria and the neglected tropical diseases (NTDs) as defined by the Centre for Diseases Control and Prevention (2011) and World Health Organization (WHO, 2015; Table 2 ).
These analyses are performed for the years 1990 and 2010.
| Concentration curves and concentration indices
We analyse concentration curves and concentration indices (Erreygers & Van Ourti, 2011 ) using data from pharmaceutical innovation. Concentration curves allow assessing the degree of drug innovation inequality by plotting the cumulative percentage of drug innovation per disease against the cumulative percentage of diseases, ranked by disease burden from the disease with lowest to the highest burden (horizontal axis). The 45°line represents a hypothetically equal distribution of drug innovation relative to disease burden. Curves lying above (under) the 45°line represent a concentration of drug innovation towards diseases with lower (greater) disease burden. We also undertake an analogous analysis substituting a measure of market size for the measure of disease burden. We use the Erreygers (2009) index E(r) to calculate concentration indices and corresponding standard errors to measure the magnitude and statistical significance of the inequality. It can be written as:
where ∑ n i¼1 γ i r i denotes the sum of drug innovation r i targeting disease i weighted by the disease ranked-dependent sum of disease burden or market size (γ i ). The term 8 n 2 b r − a r ð Þ corrects for the boundedness of the variable r i , with b r and a r , denoting, respectively, the maximum and minimum values of r i , and n the total number of diseases i (Erreygers, 2009 ). The sign of E(r) indicates the direction of the inequality: positive values indicate a pro-high disease burden dispersion whereas negative values indicate a dispersion of drug innovation in favor of disease areas with low disease burden.
Although there are other possible methodological options to calculate concentration indices, such as the health concentration index (introduced by Wagstaff, Paci, & Van Doorslaer, 1991) , the normalized health concentration index by Wagstaff (2005) , and the generalized health concentration index developed by Clarke, Gerdtham, Johannesson, Bingefors, and Smith (2002) , these are not suitable for our analysis given the nature of our data. The Erreygers' index E satisfies the four desired properties crucial for this type of analysis, namely, (a) transferability, (b) mirroring, (c) level independence, and (d) cardinal invariance (Van Doorslaer & Van Ourti, 2011). 1 Disease groups are the following: cardiovascular and circulatory diseases; chronic respiratory diseases; diabetes, urogenital, and blood and endocrine diseases; diarrhea, lower respiratory infections, meningitis, and other common infections; digestive diseases and cirrhosis of the liver; HIV/AIDS and tuberculosis; maternal disorders; mental and behavioral disorders; musculoskeletal disorders; neglected tropical diseases and malaria; neonatal disorders; neoplasms; neurological disorders; nutritional deficiencies; other communicable, maternal, neonatal, and nutritional disorders; and other non-communicable diseases. For the first property (transferability), E ensures that, in the case of our study, transfers of drug innovation from higher (lower) to lower burden (higher burden) disease areas translate into pro-low burden of disease (pro-high burden of disease) changes in the inequality index. Second, the mirror property of E ensures that a positive level of inequality is just the mirror image of the negative level of inequality (i.e., the level of inequality for health, measured by inequality indices, is just the mirror of the inequality indices for ill health and vice versa). This is true for E even when the variables used for the construction of the index are bounded (i.e., variables that do not range from any negative to any positive value). This makes E flexible enough to the point that the comparison across diseases or populations with different averages does not affect the calculation of the index. This is particularly relevant for our case because burden of disease and innovation are left-bounded variables.
Third, the level independence ensures that an equal increment of health for all individuals or innovation to all disease areas does not affect the index; that is, the index is invariant to scalar addition, even when the bounds of the variable are kept constant.
Finally, the cardinal invariance of the index ensures that a linear transformation of our variables of interest (health variable or innovation) does not affect the value of the index; that is, the measured degree of inequalities is the same, irrespective of the cardinal scale of our variable.
| Data
In this study, we combine three data sources: (a) IMS Health R&D Focus database (IMS Health, 2012) , which provides information on global pharmaceutical R&D activity and market launches linkable through the International Classification of Diseases (ICD) to (b) the GBD study from the Institute of Health Metrics and Evaluation (IHME) that includes the most recent global estimates on disease and country-specific disease burden and mortality for 1990 and 2010 (Murray et al., 2013) , and (c) World Bank statistics on national gross domestic product (GDP) per capita to proxy ability-to-pay for 1990 (World Bank, 2018 .
The IMS database is used by the pharmaceutical industry to monitor market structure and performance to inform strategic decision making. It assembles the history of all compounds in development from the early 1980s to the present, for which information is compiled from patent and regulatory filings, presentations at medical conferences, press releases, and financial information disclosed (IMS Health, 2012) . It records the progress of compounds across R&D phases, including discontinuation and market launch.
Compounds include small molecules, monoclonal antibodies, proteins, gene therapies, vaccines, and immunotherapies, as well as fixed combination products, biosimilars, in vivo imaging agents, and specialized delivery systems targeting one of the 493 possible distinctive therapeutic indications (IMS Health, 2012) . Each compound presents up to 17 different therapeutic indications. We have, therefore, considered all indications resulting in a compound-indication as our unit of analysis. These have been matched to disease-level need measures using ICD codes and medical dictionaries. After dropping compounds with missing information at the indication level (0.1% of total compound indications), we have performed analysis for 1990 and 2010, with a total of 63,402 and 59,301 compound-indication units of observation, respectively.
Using the three data sources, we construct three disease-specific variables for 1990 and 2010 to proxy: (a) global drug innovation, (b) global burden of disease, and (c) global market size.
To measure global drug innovation, we use the number of successful compounds that effectively pass the drug approval and licensing requirements by counting the number of therapies targeting a certain disease that have received market authorization in 1990 and 2010.
Although it could be argued that market launches fail to capture incremental innovations during the R&D process that never reach the market, we believe that market launches realistically capture the level of innovation effectively available to address population health needs affected by a specific disease, in a given country. Innovations that do not successfully reach the market cannot be used for that purpose. For this reason, we do not consider other potential measures of innovation such as the number of disease-specific patents, R&D investment, or disease-specific clinical trials.
We measure global disease burden using disease-specific disability adjusted life years (DALYs) as estimated in the GBD study (Murray et al., 2013) . Despite the difficulties in measuring disease burden and health outcomes (Lopez & Murray, 1998; Salomon et al., 2003) , the GBD study is the main updated source of burden of disease data publicly available for 1990 and 2010, and provides consistent and comparable cause-specific estimates for mortality and DALYs for a list of 291 diseases across 187 countries (Murray et al., 2013) . Therefore, we are able to match the ICD (10 th version) codes for each cause category and subcategory in the GBD study to a cluster of therapeutic indications targeted by the compound projects in the IMS R&D Focus dataset (IMS Health, 2012).
Market size for disease i, m it , is constructed for 1990 and 2010 by summing up across all countries that suffer from that disease, a combined measure of disease burden associated with disease i and ability-to-pay of the country in year t. We use World Bank statistics (World Bank, 2018) on national GDP per capita (measured in purchasing power parity terms at 2005 constant $US) to generate a global measure of ability-to-pay at disease level that is expressed as:
where need ijt denotes the DALYs at time t associated with disease i for country j, and GDP jt denotes the GDP per capita for country j in year t (i.e., for both years of data 1990 and 2010). We have excluded from the analysis the broad disease category Injuries as not being a target for pharmaceutical innovation. We have also excluded from the analysis the disease group nutritional deficiencies because the number of observations is insufficient to perform the disease subcategory analysis.
3 | RESULTS Table 3 shows the descriptive statistics on global drug innovation for the two broad disease groups, CDs and NCDs, in both years 1990 and 2010. Table 4 provides similar descriptive analysis for disease subcategories. There is large dispersion of innovation across broad disease groups and disease subcategories. Although CDs show a substantial increase in the number of market launches from 208 in 1990 to 1,263 in 2010, the increase is more marked for NCDs from 748 in 1990 to 15,927 in 2010 (Table 4 ). The average number of market launches for each one of the 44 diseases consisting of the broad CDs group raises from 4.73 in 1990 to more than sixfold-that is, an average of 30.07 market launches for the 42 diseases in the CDs broad group in 2010 (with standard deviations [SD] of 14.61 and 105.85 for both years, respectively). Yet the average number of market launches across NCDs shows much larger variations rising from 7.06 (SD = 14.07) to 153.14 (SD = 347.74) between 1990 and 2010.
The increasing SD in both broad disease groups hint large heterogeneity on the levels of innovation across diseases, as suggested by the descriptive analysis performed at disease subcategories level (Table 4) .
Comparisons of average market launches at disease level, when looking at descriptive statistics at disease subcategory level, also show striking differences: the average number of market launches varies from 0 to 24.33 in 1990 and from 0 to 362.67 in 2010 (Table 4) . For instance, in 1990, whereas the disease subcategory neoplasms presents an average of 10.56 new therapies across the 27 different types of cancer, the three diseases belonging to the subcategory musculoskeletal disorders exhibit an average of 24.33 new drugs. In 2010, for example, the 14 diseases that compose the subcategory diahrrea, lower respiratory infections, meningitis, and other common infectious diseases (diahrrea and LRI henceforth) exhibit an average of 16.5 new therapies launched in the market, whereas for the 12 diseases that compose the subcategory diabetes, urogenital, blood and endocrine diseases show an average of 143.42 new market launches.
Moreover, the widening differences in the SD across disease subcategories and within subcategories between 1990 and 2010 also show evidence of increasing heterogeneity in the levels of drug innovation between diseases (Table 4) . Note. Broad disease groups follow the standard disease taxonomy used by the GBD study (Murray et al., 2013) . The broad disease group Injuries is excluded from this analysis for not being a target of pharmaceutical innovation. Therefore, the following disease subcategories are excluded from this analysis: transport injuries, unintentional injuries, self-harm and interpersonal violence, forces of nature, war and legal intervention. SD, standard deviation.
There are also large variations in the causes of death and disease burden across countries. For some regions, disease burden has been persistently concentrated in the same disease groups since 1990. In developed regions, such as North America and Western Europe, NCDs have for many decades been the major causes of death and disability. Conditions such as ischemic heart disease (IHD), chronic obstructive pulmonary disease (COPD), stroke, major depressive disorder (MDD), and trachea, bronchus and lung (TBL) cancers have presented the largest need for health care and innovation (Murray et al., 2013;  Table 5 ). In many developing countries, such as those in Sub-Saharan Africa, disease burden remains concentrated in tuberculosis, lower respiratory infections (LRI), HIV/AIDS, malaria, and diarrhea (Murray et al., 2013;  Table 5 ).
However, there are regions experiencing structural changes in their epidemiological profile in the last two decades. In Southeast or East Asia and Oceania, the importance of diseases such as LRI and diarrhea, that were prevalent in 1990, was replaced by stroke and IHD as main causes of disease burden in 2010. In Latin America and Caribbean, IHD and stroke emerge as the first and second causes of death in 2010. The epidemiological transition is perhaps more evident in North Africa and the Middle East, where IHD, MDD, stroke, and low back pain are the four main causes of disease burden in 2010, contrasting with LRI, diarrhea, congenital anomalies, and IHD in 1990 (Murray et al., 2013; Table 5) .
We now present the results from the analysis performed when using concentration curves and concentration indices to evaluate the level of association between global drug innovation and global burden of disease.
3.1 | Concentration curves and concentration indices 3.1.1 | The two broad disease groups: NCDs and CDs Figure 1 illustrates the cumulative share of disease-specific innovation associated with global disease burden for both years, when ranking diseases in terms of DALYs and market size, respectively. Results from the concentration curves Note. Broad disease groups follow the standard disease taxonomy used by the GBD study (Murray et al., 2013) . The broad disease group Injuries is excluded from this analysis for not being a target of pharmaceutical innovation. Therefore, the following disease subcategories excluded from this analysis: transport injuries, unintentional injuries, self-harm and interpersonal violence, forces of nature, war and legal intervention. SD, standard deviation. and indices (Table 6) show that innovation tends to be distributed according to burden of disease but concentrated towards diseases with larger market size. When analyzing the dispersion of innovation for CDs and NCDs separately, the concentration curves suggest a concentration of innovation towards the diseases with the highest disease burden in both years ( Figure 2 ). That is, there appears to be relatively more innovation in high burden disease areas than is strictly merited, given the disease burden associated with those diseases. For instance, in 1990, CDs with associated higher burden such as lower respiratory infections (accounting for 5.23% of total DALYs in CDs in 1990) show disproportionately more innovation (i.e., 21 new therapies launched in the market), compared to relatively lower burden diseases such as, for instance, leprosy and encephalitis (accounting for 0.003% and 1.22% of total DALYs in CDs in 1990) for which there has been disproportionately less innovation (i.e., zero and three new therapies launched in the market, respectively). Similarly in 2010, for high burden diseases such as the diarrheal diseases and the group of other infectious diseases (accounting for 1.21% and 2.56% of total DALYs in CDs in 2010, respectively) there have been, respectively, 60 and 572 new therapies launched in the market, whereas there have been no market launches for echinococcosis and vitamin A deficiency (that account for 0.02% and 0.10% of total DALYs in CDs, respectively) for instance. Likewise, NCDs associated with higher disease burden in 1990 such as cerebrovascular diseases and cervical cancer (accounting for, respectively, 5.02% and 0.52% of total DALYs for NCDs in 1990) show disproportionately more innovation (i.e., six and 16 market launches, respectively) than lower burden diseases such as eating disorders and endometriosis (that receive zero and one new therapies; accounting for 0.12% and 0.03% of total DALYs for NCDs, respectively). In 2010, for instance, testicular cancer (accounting for 0.02% of total DALYs for NCDs) shows comparably lower innovation levels (with 58 new therapies launched in the market) than higher burden diseases such as nephritis and non-Hodgkin lymphoma (that account for 0.23% and 0.44% of total DALYs for NCDs in 2010, with 190 and 240 new therapies launched in the market).
The results from the concentration curves analysis are confirmed by the positive concentration indices reported in Table 6 , although the concentration index is only statistically different from zero for the case of NCDs in 1990 (p < 0.05). For NCDs in 2010 as well as for CDs in both years, despite the positive estimated concentration index, the distribution of innovation is not statistically different from the equality line, and therefore, we cannot reject the hypothesis of innovation being (equally) distributed according to disease burden. When market size is used as the basis for ranking diseases, the results are qualitatively the same as above. The curves show similar unequal concentration towards disease areas that exhibit high market size for both CDs and NCDs (Figure 3) . These results are confirmed by the positive concentration indices (Table 6 ) that show a statistically significant inequality for NCDs in 1990 (p < 0.01) and in 2010 (p < 0.05), as well as for CDs in 1990 (p < 0.01).
We have further performed Friedman tests (Friedman, 1940) to assess statistical differences in the ranking of the diseases in 1990 compared with 2010 for burden of disease, innovation and market size for both CDs and NCDs for all countries (Table 7) and for the group of developed and developing countries 2 separately (Table 7) . Namely, we assess the statistical differences between 1990 and 2010 of the ranking of the diseases (ranked according to burden of disease and market size), by considering the total disease burden and total ability-to-pay for those groups of countries separately. Tests performed for the ranking of innovation in 1990 and 2010 consider the innovation level for the specific group of countries. Results suggest that there are statistically significant differences between the disease rankings of the two years considered for both disease burden and market size (p < 0.01) and that the diseases with more innovation in 1990 are statistically different from those in 2010, with a clear shift towards NCDs. In 1990, the top three diseases in terms of innovation were other infectious diseases, other neoplasms, and endocrine nutritional and blood and immune disorders. In 2010, the top three diseases in terms of innovation were other neoplasms, endocrine nutritional, blood and immune disorders, and other mental and behavioral disorders.
In the disease subcategory analysis, for the group of NCDs, the ranking of diseases according to innovation activity differs between 1990 and 2010 for both developed and developing countries (p < 0.01). However, for the case of CDs, although the rankings of 1990 and 2010 are statistically different for developed countries (p < 0.005) we cannot reject the null hypothesis of rank similarity for developing countries.
| The four disease subcategories with highest burden
The degree of inequality in favor of high burden diseases is more pronounced within some of the disease subcategories than for the broad disease groups (as shown by the magnitude and significance of the concentration indices presented in Table 6 ). For the top four diseases that affect developed countries, there is a statistically significant skewing of innovation towards diseases with the highest disease burden in three of the four disease subcategories, which are cardiovascular and circulatory diseases, neoplasms, and musculoskeletal disorders (Figure 4a, 4b, and 4c, respectively) . These results are confirmed by the positive and statistically significant (p < 0.01) concentration indices (Table 6) .
For instance, in 1990 in the subgroup of cardiovascular and circulatory diseases, there have been 29 new therapies launched in the market for cerebrovascular diseases (that accounts for 22.39% of total DALYs in cardiovascular and circulatory diseases in 1990) but only four new drugs for cardiomyopathy and myocarditis (with 3.8% of DALYs). In 2010, ischemic heart disease (that accounts for 44% of total DALYs in cardiovascular and circulatory diseases in 2010) exhibits 187 new drugs whereas hypertensive heart diseases (that accounts for 5.19% of DALYs) shows four new drugs.
Market launches in the subcategory neoplasms show similar patterns: in 1990, for cervical cancer, there were 16 new drugs as opposed to one new drug targeting liver cancer (with the burden of disease being, respectively, 3.76% and 1.19% of total DALYs for neoplasms in 1990); in 2010, for instance, 299 new therapies targeted kidney and other urinary organ cancers (accounting for 1.95% of DALYs for neoplasms in 2010) compared with only two new drugs treating Hodgkin's disease (accounting for 0.34% of total DALYs in neoplasms). (Friedman) is that the rankings are equal. The categorization of developed and developing countries follows the United Nations (2018) classification.
*p < 0.10. **p < 0.05. ***p < 0.01.
Finally, the subcategory of musculoskeletal disorders also shows similar patterns: in 1990, rheumatoid arthritis, which accounts for 2.86% of total DALYs for musculoskeletal disorders in that year, had 19 new drugs launched in the market as opposed to 46 new drugs targeting osteoarthritis (which accounts for 8.96% of total DALYs in this disease subcategory); in 2010, the 197 new drugs targeting rheumatoid arthritis (accounting for 2.86% of total DALYs for musculoskeletal disorders in 2010) contrast with the 533 new drugs targeting osteoarthritis (which accounts for 10.1% of total DALYs for the same disease subcategory in 2010).
The results for market size are qualitatively similar for the disease subcategories cardiovascular and circulatory diseases (p < 0.01) and neoplasms (p < 0.01) but non-significant for musculoskeletal disorders (Figures 5a, 5b, and 5c ). Indeed, a close inspection of the concentration curve highlights that, for this subcategory, the direction of the inequality changes over the distribution: up to a certain level in the distribution, the innovation is concentrated towards diseases that exhibit larger market size and affordability (e.g., gout, rheumatoid arthritis, and osteoporosis), whereas in the second part of the distribution innovations tends to be concentrated towards diseases associated with lower market size and affordability (e.g., neck pain and low back pain).
Inequalities in innovation in terms of disease burden in the top four main causes of disease burden in developed countries: (a) cardiovascular and circulatory diseases, (b) neoplasms, (c) musculoskeletal disorders, and (d) mental and behavioral disorders. The concentration curves in Figures 4a and 4c start from a point other than the origin, meaning that the first disease in the distribution (i.e., the one that has the lowest disease burden on the rank) exhibits non-zero drugs launched in the market. Curves in Figure 4d show that the first disease in the distribution exhibits zero drugs launched in the market. The categorization of developed and developing countries follows the United Nations (2018) For mental and behavioral disorders results are somewhat different (Figures 4d and 5d) . The negative and significant indices (Table 6) show an unequal distribution concentrated on diseases with lower burden (except in 1990, where it is not significant) and smaller market size. Results show that, in 1990, conditions that rank lower in terms of associated disease burden such as childhood conduct disorders (accounting for 3.74% of total DALYs for mental and behavioral disorders in 1990) and schizophrenia (7.76%) exhibit disproportionately more innovation (i.e., nine new therapies each disease) than diseases that rank higher in terms of disease burden such as anxiety (14.6%) and bipolar disorders (6.78%) presenting, respectively, six and three new therapies launched in the market in 1990. For 2010, results are qualitatively similar. Disorders associated with the abuse of cannabis, opioids, and alcohol exhibit more innovation (i.e., 87 targeting the three diseases, and responsible for respectively 1.11%, 4.94% and 9.52% of the total DALYs of the subcategory mental and behavioral disorders in 2010) than conditions with larger associated burden, with dysthymia, anxiety and unipolar depressive disorders showing respectively 5.98%, 14.49%, and 34.11% of total DALYs in this disease subcategory, and eight new therapies launched in the market in 2010. The results are also qualitatively similar when looking at market size. In both years, disease areas with smaller market size (e.g., substance use disorders and child behavioral disorders in 1990, and Asperger, autism, and disorders associated with opioids abuse in 2010) show relatively more innovation than those with larger markets (e.g., dysthymia, bipolar disorders, schizophrenia, and anxiety disorders).
Differences in the magnitude of the indices between 1990 and 2010 suggest increasing inequalities in the distribution of innovation in all disease subcategories except for cardiovascular and circulatory diseases (Table 6) . Results suggest that, over time, innovation became increasingly more concentrated in diseases that rank high in terms of disease burden for subcategories such neoplasms and musculoskeletal disorders and increasingly more concentrated towards diseases that rank low in terms of disease burden for the subcategory of mental and behavioral disorders (Table 6 ). Similar results are found for market size (Table 6) .
For the disease subcategories causing the highest burden in developing countries, the concentration curves suggest a significant skewing towards diseases with higher burden and larger market size in the diarrheal diseases and LRI, and
(c)
FIGURE 6 Inequalities in innovation activity in terms of disease burden in the top causes of disease burden in developing countries: (a) diarrhea, lower respiratory infections, and others; (b) neonatal disorders; and (c) cardiovascular and circulatory disorders. Nutritional deficiencies are top ranking in disease burden in developing countries however they do not show any drug innovation activity. Therefore, this disease subcategory is not part of this analysis. There is no innovation activity in year 1990 for neonatal deficiencies. Curves in Figure 6c start from a point other than the origin, meaning that the first disease in the distribution (i.e., the one that has the lowest disease burden on the rank) exhibits for non-zero drugs launched in the market. Also, Figures 6a and 6b show distributions for which the first disease in the distribution has zero drugs launched in the market. The categorization of developed and developing countries follows the United Nations (2018) To summarize, although our results confirm quantitatively a mismatch between disease burden and innovation, we show that the pattern and direction of the inequalities are disease subcategory specific. While for some disease subcategories, our results show innovation to be concentrated towards diseases with higher burden and larger market size (i.e., cardiovascular and circulatory diseases and neoplasms), for mental and behavioral disorders and neonatal disorders there is a clear concentration of innovation in diseases with relatively lower disease burden and smaller market size. These are disease subcategories ranking top in disease burden in both the developed world (i.e., mental and behavioral disorders) and developing world (i.e., neonatal disorders).
| The particular case of NTDs and malaria
For the NTDs and malaria subcategory, our results indicate a lack of innovation targeting the highest burden NTDs that affect predominantly developing countries (Figure 8 ). The concentration indices (Table 6) show a significant unequal distribution of innovation towards diseases associated with relatively lower disease burden and market size in both years 1990 and 2010 (p < 0.01). 4 To exemplify, dengue is responsible for 0.75% of total DALYs in NTDs and malaria and exhibits 12 new drugs launched in the market in 1990, as opposed to the three new drugs targeting rabies that is associated with a much larger burden (which accounts for 3.39% of total DALYs in NTDs and malaria in that year). In 2010, malaria, responsible for 81.23% of total DALYs in NTDs and malaria, exhibited nine new drugs launched in the market as opposed to the 21 new drugs targeting Chagas disease, which accounts for a relatively smaller disease burden, that is 0.04% of total DALYs in NTDs and malaria in 2010.
| DISCUSSION
We have assessed inequality in drug innovation considering all global innovation activity across all therapeutic and disease areas for 1990 and 2010. Our results confirm, quantitatively, assertions about the mismatch between disease burden and pharmaceutical innovation. However, the direction of the inequalities varies across disease areas. 4 We have performed the analysis for NTDs only excluding malaria and although results for 2010 remain qualitatively the same, for 1990, the concentration indices are not significant suggesting that we cannot reject the hypothesis of distribution of innovation according to disease burden and market size. Results are available from the authors upon request.
(a) (b) FIGURE 8 Inequality in innovation for neglected tropical diseases (NTDs) and malaria in terms of (a) disease burden and (b) market size.
Curves in Figure 8b start from a point other than the origin, meaning that the first disease in the distribution of NTDs (i.e., the one that has the lowest disease burden on the rank) has zero drugs launched in the market [Colour figure can be viewed at wileyonlinelibrary.com]
On the one hand, in both 1990 and 2010, drug innovation has disproportionately favored diseases with higher burden and larger market size, for the cardiovascular and circulatory diseases, neoplasms and musculoskeletal disorders groups. These are diseases mostly prevalent in the developed countries, where the number of patients and the willingness-to-pay of payers makes these markets financially attractive to the pharmaceutical industry. Moreover, the increased burden of disease associated with these NCDs in developing countries (as a result of the epidemiological convergence between developed and developing countries; Murray et al., 2013; Nathan, 2011) enlarges these markets and consequently the prospects of profitability in these disease areas at global level.
On the other hand, there is a substantial misalignment between disease burden and drug innovation disfavoring the most disabling conditions in certain disease subcategories ranking top causes of death and morbidity in both developed and developing countries. These are, respectively, mental and behavioral disorders, and neonatal disorders. Drug innovation targeting top causes of burden in developed countries for diseases that are part of mental and behavioral disorders has been concentrated in disease areas that rank low in terms of associated disease burden. This result has persisted over time, and our results suggest that the associated inequality has been increasing. Likewise, innovation targeting neonatal disorders, that mostly affect developing countries, has been disproportionately concentrated in disease areas with lower burden of disease.
Also, and following a similar pattern, innovation targeting NTDs and malaria has been unequally concentrated in diseases that have a relatively low burden in the developing world. In fact, these inequalities have reduced between 1990 and 2010.
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These results strengthen the case for intervention in global R&D markets, in the form of better alignment between public and private sector R&D strategy and health need (Fauci & Morens, 2012; Nathan, 2011) and the urgent need to redesign public policies (Cech, 2005) to foster innovation in neglected disease areas in both developed and developing countries.
Finally, our results suggest some inertia in pharmaceutical industry R&D strategies with regards to developing innovation targeted at CDs prevalent in developing countries, over the last two decades. This implies that, in those countries, morbidity and mortality associated with those diseases will remain unaddressed. Therefore, although those that suffer from NCDs will benefit from novel treatments, others will not have any innovation to address their needs. This may result in widening inequalities within developing countries (Marmot, 2005; Monteiro, Moura, Conde, & Popkin, 2004) .
Due to the nature of our data, there are several caveats to our analysis. First, we cannot distinguish the degree of novelty of drugs in our data. Therefore, our measure of innovation includes both disruptive innovations, with added value with regards to other existing treatments, as well as incremental innovations, and those that not necessarily incrementally improve population health, that is "me-too" drugs (Organisation for Economic Co-operation and Development, 2005) . Given that we have no information about the efficacy of the drugs, we give these different types of innovation equal weight in mitigating burden of disease in our analysis. Because our results rely on disease rankings across burden of disease, this could potentially be an issue if the distribution of drugs with different efficacy differs across and within diseases. To further investigate this, we would need data on the degree of novelty and clinical evidence for each drug launched in the market. Unfortunately, these data are not available. The existing efficacy data are mostly from clinical trials reported in systematic reviews (Kaplan et al., 2013; Kaplan & Laing, 2004 ) and thus does not capture comprehensively innovations and is also subject to publication bias. Assessing innovation inequalities using the value of innovation is an important research question that can be addressed if further investment is made in data on the efficacy of drugs in clinical trials, as well as surveillance data on the effectiveness of drugs once launched in the market.
Secondly, we have no information on the cost-effectiveness of the different drugs launched in the market; hence, we give equal weight to drugs that might offer different value for money in comparison with existing treatment alternatives. It could be, however, that some of these innovations are not truly cost-effective, and therefore, their market launch does not bring value for money in mitigating burden of disease. For these reason, and in light of our analysis, it should be remarked that equal distribution of drug innovation, in line with disease burden, is not necessarily desirable or expected. Even though drugs deliver potentially large health benefits, there are other alternative more cost-effective (health or non-health related) interventions that may be more suitable to address certain types of conditions.
Embedding cost-effectiveness in inequalities analysis is an important avenue of research that requires substantial data investment. Yet measuring cost-effectiveness for drugs across different countries is potentially even more complex than measuring efficacy and effectiveness. Indeed, the direct and indirect costs and benefits used in cost-effectiveness analysis are country specific and depend on the scope and organization of service delivery in the different health systems (Paris & Belloni, 2016) .
Thirdly, the availability of new therapies in the market depends on national policies and socioeconomic realities that make the drugs more or less accessible to those that most need them. Our data do not allow us to assess utilization of drugs. It could be, however, that for certain disease areas, drugs are launched in some countries and are only accessible to a subgroup of the population. Without information on drug utilization, we could potentially be underestimating inequalities in our analysis.
Finally, our analysis does not assess the reasons behind an unequal distribution of market launches across disease areas. It could be that differences in innovation across disease areas reflect not only strategic behavior of the industry but also the differences in the technical and scientific risk of developing a new molecule across disease areas. Disentangling these determinants of innovation is of key importance for the design of effective innovation reward systems that seek to incentivize innovation and mitigate disease burden in specific disease areas.
Nevertheless, given the substantial investment in pharmaceutical R&D, for efficiency and equity reasons, it is important to assess the societal returns on such investments, and in particular, whether current R&D efforts are focusing sufficient attention on the priority areas of need. Therefore, notwithstanding the caveats, our findings are important and can be instrumental in informing policy-making for prioritizing diseases for R&D investment that meets global population health needs.
